This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bayer, A S Articles by Kim, K S Search for Related Content PubMed PubMed Citation Articles by Bayer, A S Articles by Kim, K S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 January; 31(1): 70-75

Characterization of impermeability variants of Pseudomonas aeruginosa isolated during unsuccessful therapy of experimental endocarditis.

A S Bayer, D C Norman and K S Kim

ABSTRACT

We characterized five amikacin-resistant variants of Pseudomonas aeruginosa isolated from aortic valve vegetations during unsuccessful therapy of experimental endocarditis. These organisms were cross resistant to other aminoglycosides. No aminoglycoside-modifying enzymes were produced by these strains. However, all five variants demonstrated significant defects in permeability and intracellular uptake of [3H]amikacin when compared with the amikacin-susceptible parental strain (0 to 26% of that of the parental strain; mean, approximately 15%). The permeability defects were unstable in vitro, with normalization after serial passage in antibiotic-free media. The variants grew as nonpigmented, small-colony types, with in vitro generation times approximately 1.5 to 2 times longer than that of the parental strain (30 to 40 versus 20 min, respectively). Two impermeability variants were compared with the parental strain for ability to induce experimental endocarditis in rabbits with aortic catheters. Both variants were virulent in vivo; however, mean bacterial densities in vegetations were approximately 2.5 log10 CFU/g lower in animals challenged with the variants than in animals challenged with the parental strain, probably reflecting a slower in vivo growth rate.

---

Antimicrob Agents Chemother. 1987 January; 31(1): 70-75

This article has been cited by other articles:

• Hocquet, D., Vogne, C., El Garch, F., Vejux, A., Gotoh, N., Lee, A., Lomovskaya, O., Plesiat, P. (2003). MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrob. Agents Chemother. 47: 1371-1375 [Abstract] [Full Text]  
• Roggenkamp, A., Sing, A., Hornef, M., Brunner, U., Autenrieth, I. B., Heesemann, J. (1998). Chronic Prosthetic Hip Infection Caused by a Small-Colony Variant of Escherichia coli. J. Clin. Microbiol. 36: 2530-2534 [Abstract] [Full Text]